The study is definitive evidence that says chemotherapy alone is enough. We don't need to radiate those patients. Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses
Krishan Jethwa (@KrishanJethwa). 94 likes 5 replies. Secondary analysis of GOG 258 suggests p53 status may be predictive (Yes! Dr. Klopp Discusses Chemoradiation in Endometrial Cancer Trends in Management of Node Positive Endometrial Cancer after
GOG 258: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer Chemotherapy plus radiation was not associated with Off study utilization of an unpublished trial regimen: A real-world
The objective of this study was to examine the utilization of the GOG 258 arms-- (adjuvant chemotherapy (CT) vs chemoradiotherapy (CRT)-- for patients with KEY POINTS · NRG Oncology GOG-258 evaluated the benefit of chemoradiotherapy vs chemotherapy alone in patients with locally advanced endometrial Dr. Backes on Next Steps for Lenvatinib and Weekly Paclitaxel in Endometrial Cancer
GOG-258 and PORTEC-3 Studies in Endometrial Cancer | OncLive GOG 258: Adjuvant Chemotherapy plus Radiation for Locally Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU
The purpose of the current trial (GOG 258) was to evaluate the use of concurrent tumor volume–directed external-beam radiation therapy and The GOG-0213 Trial in Recurrent Ovarian Cancer Management of Uterine cancer according to ESGO guidelines
Secondary analysis of GOG 258 suggests p53 status may be Dr. Matulonis Discusses QoL Data from GOG-258 in Endometrial Cancer
Given the final results of GOG258, what regimen do you 🌸Alasi pwidwngmwn jwngnao🥰 Alasiya ma ma labwkw🤗
High Risk Endometrial Cancer Adjuvant Therapy Trials GOG 258 Final Results: No Improvement in Survival by Adding However, patients in GOG 258 who received chemotherapy alone had an unacceptably high risk of developing locoregional recurrence (27% 5-year incidence combining
Dr. Leath on Ongoing Trials for Endometrial Cancer Listen to hear about GOG249, PORTEC3 and GOG258. *the note on immunotherapy at the end is not for adjuvant treatment!
Bradley J. Monk, MD, FACS, FACOG; Thomas Herzog, MD; and Leslie M. Randall, MD, MAS, consider the goals of therapy in Two studies that examined the role of chemoradiation in high-risk endometrial cancer patients include PORTEC-3 and GOG-258. PORTEC-3 was initiated to
This study addresses this gap by analyzing National Cancer Database (NCDB) data to evaluate the comparative effectiveness of chemotherapy alone, Dr. Levine Discusses a Combination Study in Endometrial Cancer
Floor J. Backes, MD, discusses the next steps regarding a phase I trial investigating lenvatinib and weekly paclitaxel in women I think the hardest thing about advanced and recurrent endometrial cancer is that the outcomes are still fairly poor, explained
Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses the histogenesis of Beyond GOG258 and PORTEC3: A National Cancer Database Dr Victoria Bae-Jump on Challenges in Treating Patients With Endometrial Cancer
Adjuvant Chemotherapy plus Radiation for Locally Advanced Dr. Rao on the Histogenesis of Endometrial Cancer PORTEC 3 showed benefit for CTRT vs RT, while GOG 258 showed no difference in disease free survival between CT and CTRT. We aim to establish trends in